ArticleRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2025
[Pneumococcal meningitis in a tertiary care hospital: clinical characteristics, serotype distribution, and vaccination status].
Article in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPneumococcal meningitis is a severe form of invasive pneumococcal disease (IPD). Despite the changes introduced by conjugate vaccines, pneumococcal meningitis remains a major clinical and public health challenge. Analyzing its current patterns allows the identification of serotypes that retain a higher invasive potential, the assessment of their relationship with clinical outcomes, and the guidance of future preventive strategies.
methodsRetrospective descriptive study of patients with pneumococcal meningitis admitted between 2018 and 2024. Clinical, demographic, and microbiological variables were analyzed, including identified serotypes, markers of severity (ICU, intubation, death), vaccination status, and antimicrobial sensitivity.
resultsThirty-six cases of pneumococcal meningitis were identified (8 pediatric, 28 adults), with a case fatality rate of 19.4% and an ICU admission rate of 69.4%. The serotype was identified in 88.9% of cases, with 17 different serotypes detected. The most aggressive serotypes were 8, 3, 16, 33, and 23B, and the most lethal were 8, 3, 23A, 25A, and 9N. Seventy-five percent of adults had an indication for vaccination, but only half had received any doses. Resistance to cefotaxime was documented in three strains (9N, 19A, 23F), one of which was associated with a fatal outcome.
conclusionPneumococcal meningitis remains a serious condition. Serotypes such as 8 and 3 are associated with high mortality rates. Low vaccination coverage in at-risk groups represents a critical gap in prevention. Knowing the serotypes involved and their resistance profiles is key to adapting vaccination strategies and reducing the burden of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.